Glaukos Corporation (GKOS)
Stock Price:
$71.79 USD
2.25 (3.23%)
Updated December 3, 2:23 PM EST - Market open
Key Info
| Market Cap |
3.23B |
| Revenue (ttm) |
217.57M |
| Net Income (ttm) |
-73.12M |
| Shares Out |
44.71M |
| EPS (ttm) |
-1.70 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
December 3 |
| Last Price |
$71.79 |
| Previous Close |
$69.54 |
| Change ($) |
2.25 |
| Change (%) |
3.23% |
| Day's Open |
69.45 |
| Day's Range |
69.45 - 71.96 |
| Day's Volume |
177,651 |
| 52-Week Range |
25.53 - 71.96 |
More Stats
| Market Cap |
3.23B |
| Enterprise Value |
3.10B |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
44.71M |
| Float |
n/a |
| EPS (basic) |
-1.50 |
| EPS (diluted) |
-1.70 |
| FCF / Share |
-0.98 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
4.99M |
| Short Ratio |
8.33 |
| Short % of Float |
n/a |
| Beta |
1.87 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
14.83 |
| PB Ratio |
4.49 |
| Revenue |
217.57M |
| Operating Income |
-141.86M |
| Net Income |
-73.12M |
| Free Cash Flow |
-43.77M |
| Net Cash |
131.65M |
| Net Cash / Share |
2.93 |
| Gross Margin |
93.02% |
| Operating Margin |
-65.20% |
| Profit Margin |
-33.60% |
| FCF Margin |
-20.12% |
| ROA |
-7.40% |
| ROE |
-17.17% |
| ROIC |
-31.00% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (10)
| Buy |
3 |
| Overweight |
0 |
| Hold |
4 |
| Underweight |
1 |
| Sell |
2 |
Analyst Consensus: Overweight
Price Target
$55.89*
(-22.14% downside)
Low
48.0
Current: $71.79
High
70.0
Target: 55.89
*Average 12-month price target from 9 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | 237 | 181 | 159 | 114 | 71.70 | 45.59 | 20.95 |
| Revenue Growth | 30.73% | 13.83% | 39.21% | 59.55% | 57.28% | 117.64% | - |
| Gross Profit | 198 | 156 | 138 | 98.22 | 58.71 | 34.17 | 18.41 |
| Operating Income | -50.29 | -13.00 | -2.28 | 4.24 | -10.30 | -13.17 | -14.20 |
| Net Income | 15.42 | -12.95 | -0.09 | 4.52 | -37.24 | -12.13 | -12.64 |
| Shares Outstanding | 37.36 | 35.32 | 34.38 | 32.93 | 17.47 | 2.29 | 2.04 |
| Earnings Per Share | 0.37 | -0.37 | - | 0.12 | -2.13 | -5.29 | -6.21 |
| Operating Cash Flow | -0.37 | 18.86 | 26.09 | 12.31 | -2.19 | -7.11 | -13.31 |
| Capital Expenditures | -4.72 | -10.32 | -6.31 | -6.28 | -0.88 | -0.87 | -0.85 |
| Free Cash Flow | -5.09 | 8.55 | 19.78 | 6.03 | -3.07 | -7.98 | -14.16 |
| Cash & Equivalents | 183 | 149 | 119 | 95.84 | 91.20 | 2.36 | 6.79 |
| Total Debt | 72.63 | - | - | - | 9.70 | 19.35 | 17.50 |
| Net Cash / Debt | 111 | 149 | 119 | 95.84 | 81.51 | -16.99 | -10.71 |
| Assets | 818 | 207 | 166 | 134 | 117 | 26.02 | 30.88 |
| Liabilities | 145 | 33.11 | 27.63 | 17.10 | 21.47 | 29.55 | 23.71 |
| Book Value | 673 | 174 | 138 | 117 | 95.19 | -151 | -141 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Glaukos Corporation |
| Country |
United States |
| Employees |
600 |
| CEO |
Thomas Burns |
Stock Information
| Ticker Symbol |
GKOS |
| Stock Exchange |
NYSE |
| Sector |
Healthcare |
| Industry |
Medical Instruments & Supplies |
| Unique Identifier |
NYSE: GKOS |
| IPO Date |
June 25, 2015 |
Description
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite for use as a standalone procedure in patients with refractory glaucoma; iStent SA, a two-stent product that is designed for use as a standalone glaucoma procedure; iDose Travoprost, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication; and MicroShunt, an ab-externo device for treatment of open-angle glaucoma. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was founded in 1998 and is headquartered in San Clemente, California.